G Protein-Coupled Receptors (GPCRs) in advancing GPCR-targeted therapies, including the use of agonists, antagonists, biased ...

Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, develops and licenses biopharmaceutical assets worldwide. It offers Pradefovir, Posaconazole, Voriconazole, CAPVAXIVE, NOXAFIL ...

Artificial intelligence (AI) is making significant strides in various fields, with drug discovery being one of the most impactful areas. The process of developing new drugs has traditionally been a ...

Tovecimig, formerly known as CTX-009, is a bispecific antibody that blocks the Delta-like ligand 4 and vascular endothelial growth factor A signaling pathways.

Upon close of merger and $78.9mm concurrent private placement from a syndicate of leading healthcare-dedicated investors, completed ...

CHENGDU, China I March 25, 2025 I Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "Company") announced that the Company has received a clinical ...

During a live event, Catherine J. Lee, MD, MS, discussed the mechanism of action of approved therapies for chronic ...

Otsuka Pharmaceutical Development & Commercialization Inc. filed its BLA with the U.S. FDA for sibeprenlimab to treat immunoglobulin A nephropathy (IgAN). The company’s first BLA, sibeprenlimab is a ...

The Food and Drug Administration (FDA) has approved Imfinzi ® (durvalumab), in combination with gemcitabine and cisplatin as neoadjuvant treatment, followed by single agent Imfinzi as adjuvant ...

Biotech’s radionuclide-drug conjugate SKB107 receives China NMPA approval to treat bone metastases in solid tumours: Chengdu, China Friday, March 28, 2025, 15:00 H ...